Efficacy of PI3K inhibitors in advanced breast cancer.

Animals Antineoplastic Agents / pharmacology Breast Neoplasms / drug therapy Class I Phosphatidylinositol 3-Kinases / antagonists & inhibitors Clinical Trials as Topic Female Humans Mutation Neoplasm Metastasis Protein Kinase Inhibitors / pharmacology Randomized Controlled Trials as Topic Signal Transduction / drug effects
PI3K inhibitors breast cancer targeted therapy

Journal

Annals of oncology : official journal of the European Society for Medical Oncology
ISSN: 1569-8041
Titre abrégé: Ann Oncol
Pays: England
ID NLM: 9007735

Informations de publication

Date de publication:
12 2019
Historique:
entrez: 14 1 2020
pubmed: 14 1 2020
medline: 26 8 2020
Statut: ppublish

Résumé

The phosphoinositide 3 (PI3)-kinase/Akt signaling pathway has always been a focus of interest in breast cancer due to its role in cell growth, cell proliferation, cell migration and deregulated apoptosis. Its activation has been linked to endocrine resistance and worse prognosis in certain subgroups of breast cancer. In addition, deregulation of the PI3K/Akt pathway including PIK3CA activating mutation is frequently present in breast cancer. Multiple efforts have been carried out to target this pathway, initially with pan-PI3K inhibitors with some hint of activity but hampered by their limiting side-effects. A recent large randomized trial in patients with endocrine-resistant PIK3CA-mutant hormone receptor (HR)-positive tumors led to the approval of the first PI3K inhibitor, alpelisib, in combination with fulvestrant. The specificity of alpelisib against the p110α catalytic isoform provided additional efficacy and a better toxicity profile. In this review, we summarize the main research with PI3K inhibitors in breast cancer and we provide some insight of potential future combinations of this treatment in breast cancer patients.

Identifiants

DOI: 10.1093/annonc/mdz381 PMID: 31928690
pubmed: 31928690
pii: S0923-7534(20)34374-X
doi: 10.1093/annonc/mdz381
pii:
doi:

Substances chimiques

Antineoplastic Agents 0
Protein Kinase Inhibitors 0
Class I Phosphatidylinositol 3-Kinases EC 2.7.1.137
PIK3CA protein, human EC 2.7.1.137

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

x12-x20

Informations de copyright

© 2019 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.

Auteurs

B Verret (B)

Medical Oncology Department, Gustave Roussy Cancer Campus, Villejuif, France.

J Cortes (J)

IOB Institute of Oncology, Quiron, Madrid & Barcelona; Department of Medical Oncology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona; Medica Scientia Innovation Research (MedSIR), Valencia, Spain; Medica Scientia Innovation Research (MedSIR), New York, USA.

T Bachelot (T)

Medical Oncology Department, Centre Léon Bérard, Lyon.

F Andre (F)

Medical Oncology Department, Gustave Roussy Cancer Campus, Villejuif, France; Inserm Unit U981, Gustave Roussy Cancer Campus, Villejuif; Université Paris Sud, Paris-Saclay, France.

M Arnedos (M)

Medical Oncology Department, Gustave Roussy Cancer Campus, Villejuif, France; Inserm Unit U981, Gustave Roussy Cancer Campus, Villejuif. Electronic address: monica.arnedos@gustaveroussy.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Efficacy of PI3K inhibitors in advanced breast cancer.
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Efficacy of PI3K inhibitors in advanced breast cancer.
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Maladies du sein › Tumeurs du sein › Efficacy of PI3K inhibitors in advanced breast cancer.
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines et peptides de signalisation intracellulaire › Phosphatidylinositol 3-kinases › Phosphatidylinositol-4-phosphate 3-kinase › Phosphatidylinositol 3-kinases de classe I › Efficacy of PI3K inhibitors in advanced breast cancer.
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études cliniques comme sujet › Essais cliniques comme sujet › Efficacy of PI3K inhibitors in advanced breast cancer.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Efficacy of PI3K inhibitors in advanced breast cancer.
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › Efficacy of PI3K inhibitors in advanced breast cancer.
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Métastase tumorale › Efficacy of PI3K inhibitors in advanced breast cancer.
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Inhibiteurs de protéines kinases › Efficacy of PI3K inhibitors in advanced breast cancer.
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études cliniques comme sujet › Essais cliniques comme sujet › Essais cliniques contrôlés comme sujet › Essais contrôlés randomisés comme sujet › Efficacy of PI3K inhibitors in advanced breast cancer.
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Transduction du signal › Efficacy of PI3K inhibitors in advanced breast cancer.